Summary of adverse events
| Event . | Total (N = 63) . |
|---|---|
| Most common adverse events of any grade* | |
| Fatigue | 28 (44) |
| Diarrhea | 27 (43) |
| Anemia | 21 (33) |
| Nausea | 16 (25) |
| Arthralgia | 15 (24) |
| Peripheral edema | 15 (24) |
| Thrombocytopenia | 15 (24) |
| Cough | 14 (22) |
| Dyspnea | 13 (21) |
| Upper respiratory tract infection | 13 (21) |
| AEs grade ≥3† | |
| Anemia | 9 (14) |
| Pneumonia | 5 (8) |
| Fatigue | 4 (6) |
| Cellulitis | 3 (5) |
| Diarrhea | 3 (5) |
| Hypertension | 3 (5) |
| Lymphocyte count decreased | 3 (5) |
| Neutropenia | 3 (5) |
| Asthenia | 2 (3) |
| Autoimmune hemolytic anemia | 2 (3) |
| Blood bilirubin increased | 2 (3) |
| Muscle spasms | 2 (3) |
| Multiple organ dysfunction | 2 (3) |
| Neutrophil count decreased | 2 (3) |
| Pneumothorax | 2 (3) |
| Sepsis | 2 (3) |
| Serious AEs‡ | |
| Pneumonia | 5 (8) |
| Cellulitis | 2 (3) |
| Autoimmune hemolytic anemia | 2 (3) |
| Pneumothorax | 2 (3) |
| Sepsis | 2 (3) |
| Event . | Total (N = 63) . |
|---|---|
| Most common adverse events of any grade* | |
| Fatigue | 28 (44) |
| Diarrhea | 27 (43) |
| Anemia | 21 (33) |
| Nausea | 16 (25) |
| Arthralgia | 15 (24) |
| Peripheral edema | 15 (24) |
| Thrombocytopenia | 15 (24) |
| Cough | 14 (22) |
| Dyspnea | 13 (21) |
| Upper respiratory tract infection | 13 (21) |
| AEs grade ≥3† | |
| Anemia | 9 (14) |
| Pneumonia | 5 (8) |
| Fatigue | 4 (6) |
| Cellulitis | 3 (5) |
| Diarrhea | 3 (5) |
| Hypertension | 3 (5) |
| Lymphocyte count decreased | 3 (5) |
| Neutropenia | 3 (5) |
| Asthenia | 2 (3) |
| Autoimmune hemolytic anemia | 2 (3) |
| Blood bilirubin increased | 2 (3) |
| Muscle spasms | 2 (3) |
| Multiple organ dysfunction | 2 (3) |
| Neutrophil count decreased | 2 (3) |
| Pneumothorax | 2 (3) |
| Sepsis | 2 (3) |
| Serious AEs‡ | |
| Pneumonia | 5 (8) |
| Cellulitis | 2 (3) |
| Autoimmune hemolytic anemia | 2 (3) |
| Pneumothorax | 2 (3) |
| Sepsis | 2 (3) |
Data are presented as n (%) of patients unless indicated otherwise.
The events listed are AEs of any grade that occurred in at least 20% of patients.
The events listed are AEs of grade 3 or higher that occurred in at least 2 patients (3%).
The events listed are serious AEs that occurred in at least 2 patients (3%). The list of all serious AEs is provided in supplemental Table 3.